1. Medtech Insight

Minute Insight: Abbott’s Aveir VR To Take On Medtronic’s Micra In US Leadless Pacemaker Market

 
• By Reed Miller

The US FDA approved Aveir VR to treat significant bradycardia on 4 April. It is the world’s only leadless pacemaker with Abbott’s proprietary mapping capability that helps physicians correctly position the device inside the right ventricle.

Minute Insight
• Source: Informa/Alamy

The US Food and Drug Administration approved a premarket approval application (PMA) for Abbott’s Aveir VR single-chamber leadless pacemaker, the company announced on 4 April.

Aveir VR is indicated for the treatment of people with significant bradycardia, chronic atrial fibrillation, and severe physical disability, but contraindicated for people who have frequent episodes of atrioventricular block...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Minute Insights

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.